Bicyclol in the treatment of patients with chronic diffuse liver diseases

Introduction. The increase in serum transaminases (ALT and AST) and the persistence of their high values is associated with morbidity and mortality from liver diseases. Bicyclol has anti-inflammatory and antioxidant effects, which formed the basis for this study.

Materials and methods. The study enrolled 51 patients (MELD < 19); hepatitis stage – 84.4%, cirrhosis – 15.6%. Treatment: Bicyclol 75 mg/day for 12 weeks. Criteria of efficacy: dynamics of ALT, AST, CRP; general well-being (D-FIS scale).

Results. After 4 weeks of treatment the share of patients with ALT normalization was 50,9% (p < 0,001); with AST normalization – 62.7% (p < 0.001); after 12 weeks - 79,5% and 89,7% respectively (p < 0,001). CRP decreased statistically significantly after 2 and 4 weeks from the beginning of treatment. The D-FIS questionnaire was filled in by 36 patients at the beginning of the study, in 4 weeks - by 35 patients, in 12 weeks – by 32 patients. Median D-FIS decreased from 12 (8.2; 32.2) to 8 (5; 29) points (p < 0,001) after 4 weeks of treatment, after 12 weeks – to 6.5 (3; 28.5) points (p < 0.001). The CRP was positively correlated with the D-FIS value. Fibrosis (“Fibromax”, “Fibroscan”) was studied in 10 additional patients, the dose of Bicyclol was 150/75 mg/day during 6 months, the result was statistically significant (p < 0.001).

Conclusion. Application of Bicyclol leads to reduction of fatigue, local and systemic inflammation, fibrosis in chronic diffuse liver diseases regardless of etiology.

1. Ivashkin V.T., Mayevskaya M.V., Zharkova M.S., Tikhonov I.N., Fedosina E.A., Pavlov CH.S. Algorithms of diagnostics and treatment in hepatology. Moscow: MEDpress-Inform; 2016. 176 p. (In Russ.) Available at: https://www.rsls.ru/files/news/Present2208.pdf.

2. Kwo P.U., Cohen S.M., Lim J.K. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18–35. doi: 10.1038/ajg.2016.517.

3. Ruhl C.E., Everhart J.E. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology. 2012;55(2):447–454. doi: 10.1002/hep.24725.

4. Arndt V., Brenner H., Rothenbacher D., Zschenderlein B., Fraisse E., Fliedner T.M. Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality. Int Arch Occup Environ Health. 1998;71:405–412. doi: 10.1007/s004200050299.

5. Chang Kim Hyeon, Mo Nam Chung, Ha Jee Sun, Hyub Han Kwang, Dae Kyu Oh, Il Suh. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983. doi: 10.1136/bmj.38050.593634.63.

6. Lee T.H., Kim W.R., Benson J.T., Therneau T.M., Melton III L.J. Serum aminotransferase activity and mortality risk in a United States community. Hepatology. 2008;47(3):880–887. doi: 10.1002/hep.22090.

7. Ruhl C.E., Everhart J.E. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology. 2009;136(2):477–485. doi: 10.1053/j.gastro.2008.10.052.

8. Shang W., Feng Y., Li J., Wang X., Xie H., Feng G. Effect of bicyclol tablets on drug induced liver injuries after kidney transplantation. Open Medicine. 2017;12(1):62–69. doi: 10.1515/med-2017-0012.

9. Naqiong W., Liansheng W., Zhanying H., Yuanlin G., Chenggang Z., Ying G. et al. A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury. Med Sci Monit. 2017;23:5760–5766. doi: 10.12659/msm.904090.

10. Zhang Y., Xie Y., Zhang Y., Liu Y., Zhuang Y. Hepatitis B patients exhibiting mild alanine aminotransferase elevation: A comparative analysis of treatment with and without Bicyclol tablets. Biomed Rep. 2016;5(5):595–600. doi: 10.3892/br.2016.765.

11. Xie W., Shi G., Zhang H., Zhao G., Yu Z., Lang Z. et al. A randomized, multicentral, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatol Int. 2012;6(2):441–448. doi: 10.1007/s12072-011-9294-7.

12. Wang Y., Nie H., Zhao X., Qin Y., Gong X. Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer. 2016;16:742. doi: 10.1186/s12885-016-2767-2.

13. Li M., Liu G.-T. Inhibition of Fas/FasL mRNA expression and TNF-α release in concanavalin A-induced liver injury in mice by bicyclol. WJG. 2004;10(12):1775–1779. doi: 10.3748/wjg.v10.i12.1775.

14. Liu G.-T., Li Y., Wei H.-L., Lu H., Zhang H., Gao Y.-G. et al. Toxicity of novel anti-hepatitis drug bicyclol: A preclinical study. WJG. 2005;11(5):665–671. doi: 10.3748/wjg.v11.i5.665.

15. Bao Xiu-qi, Liu Geng-tao. Bicyclol protects HepG2 cells against D-galactosamine-induced apoptosis through inducing heat shock protein 27 and mitochondria associated pathway. Acta Pharmacologica Sinica. 2010;31(2):219–226. doi: 10.1038/aps.2009.194.

16. Cui J., Li Z., Qian L., Gao Q., Xue M., Lou Xaio-e et al. Reducing the oxidative stress mediates the cardioprotection of bicyclol against ischemiareperfusion injury in rats. Journal of Zhejiang University Science B. 2013;14(6):487–495. doi: 10.1631/jzus.B1200263.

17. Green R.M., Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1367–1384. doi: 10.1053/gast.2002.36061.

18. Malakouti M., Kataria A., Ali S.K., Schenker S. Elevated Liver Enzymes in Asymptomatic Patients – What Should I Do? J Clin Transl Hepatol. 2017;5(4):394–403. doi: 10.14218/JCTH.2017.00027.

19. Fisk J.D., Doble S.E. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res. 2002;11(3):263–272. doi: 10.1023/a:1015295106602.

20. Swain M.G. Fatigue in liver disease: pathophysiology and clinical management. Can J Gastroenterol. 2006;20(3):181–188. doi: 10.1155/2006/624832.

21. Kiecolt-Glaser J.K., McGuire L., Robles T.F., Glaser R. Psychoneuroimmunology and psychosomatic medicine: Back to the future. Psychosom Med. 2002;64(1):15–28. doi: 10.1097/00006842-200201000-00004.

22. Larson S.J., Dunn A.J. Behavioral effects of cytokines. Brain Behav Immun. 2001;15(4):371–387. doi: 10.1006/brbi.2001.0643.